vitamin-u and Colitis--Ulcerative

vitamin-u has been researched along with Colitis--Ulcerative* in 2 studies

Trials

1 trial(s) available for vitamin-u and Colitis--Ulcerative

ArticleYear
Role of sulphydryl-containing agents in the management of recurrent attacks of ulcerative colitis. A new approach.
    Pharmacology, 1992, Volume: 45, Issue:6

    This double-blind randomised study investigated the role of sulphydryl-containing agents in the management of recurrent attacks of ulcerative colitis. To this end, DL-cysteine (200 mg 4 times daily) and DL-methionine-methyl sulphonium chloride (MMSC, 500 mg 4 times daily) were administered orally. Patients with recurrent attacks of moderate proctosigmoidal ulcerative colitis, despite prophylaxis by oral sulphasalazine (2 g daily), were given prednisolone by mouth, 10 mg four times a day, sulphasalazine by mouth, 500 mg four times a day, and morning and evening retention enema (Predsol 20 mg) alone or with cysteine or MMSC. After 2 weeks of treatment with sulphasalazine and prednisolone, 51% of patients (n = 45) were symptom free. Addition of cysteine (n = 46) or MMSC (n = 47) to this regimen controlled the symptoms within 2 weeks in 85% of patients (p < 0.01). During 12 months of prophylactic treatment, 5% of patients (n = 42) receiving sulphasalazine (2 g daily) and cysteine and 5% of patients (n = 41) taking sulphasalazine (2 g daily) and MMSC relapsed, relative to 27% of cases with sulphasalazine (2 g daily) alone (p < 0.01). These results demonstrate that sulphydryl-containing agents play a key role in the treatment of and protection against ulcerative colitis.

    Topics: Adult; Aged; Anti-Ulcer Agents; Colitis, Ulcerative; Cysteine; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Prednisolone; Prospective Studies; Recurrence; Sulfasalazine; Sulfhydryl Compounds; Vitamin U

1992

Other Studies

1 other study(ies) available for vitamin-u and Colitis--Ulcerative

ArticleYear
Methionine derivatives diminish sulphide damage to colonocytes--implications for ulcerative colitis.
    Gut, 1996, Volume: 39, Issue:1

    Bacterial production of anionic sulphide is increased in the colon of ulcerative colitis and sulphides can cause metabolic damage to colonocytes.. To assess the reversal of the damaging effect of sulphide to isolated colonocytes by methionine and methionine derivatives.. Isolated colonocytes were prepared from rat colons and 12 human colectomy specimens. In cell suspensions 14CO2/acetoacetate generation was measured from [1-14C]-butyrate (5.0 mmol/l) in the presence of 0-2.0 mmol/l sodium hydrogen sulphide. The effect of 5.0 mmol/l L-methionine, S-adenosylmethionine 1,4 butane disulphonate and DL-methionine-S-methylsulphonium chloride on sulphide inhibited oxidation was observed.. In rat colonocytes sodium hydrogen sulphide dose dependently reduced oxidative metabolite formation from n-butyrate, an action reversed in order of efficacy by S-adenosylmethionine 1,4 butane disulphonate > DLmethionine-S-methyl-sulphonium chloride > L-methionine. In human colonocytes S-adenosylmethionine 1,4 butane disulphonate most significantly improved 14CO2 production (p = < 0.005) suppressed by sodium hydrogen sulphide.. Sulphide toxicity in colonocytes is reversible by methyl donors. The efficiency of sulphide detoxification may be an important factor in the pathogenesis and treatment of ulcerative colitis for which S-adenosylmethionine 1,4 butane disulphonate may be of therapeutic value.

    Topics: Acetamides; Animals; Butyrates; Butyric Acid; Carbon Dioxide; Carbon Radioisotopes; Cells, Cultured; Colitis, Ulcerative; Colon; Humans; Male; Methionine; Rats; Rats, Sprague-Dawley; S-Adenosylmethionine; Scintillation Counting; Sulfides; Vitamin U

1996